Search

GnRH pharmaccine

The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation … The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle".

Cisplatin

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lympho...

Imetelstat

[A187838] Imetelstat received FDA approval in June 2024 for use in certain patients with MDS who have transfusion-dependent anemia and are unable to use ESAs.[L50883,L50888] … Imetelstat is a first-in-class 18-amino acid oligonucleotide that directly and competitively inhibits human telomerase.

Levmetamfetamine

Levomethamphetamine, the L-enantiomer of methamphetamine is a sympathomimetic vasoconstrictor used in some over-the-counter (OTC) nasal decongestant inhalers in the United States.

Gepotidacin

[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … [L52680,L52685] In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. [L54803]

(-)-menthol 1-propylene glycol carbonate

EVT 302

EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

Ruplizumab

Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.

Guanoxan

Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. … Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.

Clobutinol

Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.